Descriptive analysis identifies treatment patterns and disease trends in HR+/HER2- metastatic breast cancer in England, highlighting care gaps.
There are limited real world data on the patterns of care of patients in England with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). Here we describe the epidemiology and treatment of HR+ HER2- mBC using national databases in England over a decade.
No takes yet. Share an insight, caveat, or question.
Makris et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: